

## HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

## Angiotensin Modulators

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:		Prescriber Name:		
HPP Member Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Patient Primary Phone:		NPI:	PA PROMISe ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Line of Business: ☐ Medicaid ☐ CHIP		Specialty Pharmacy (if applicable):		
Drug Name:		Strength:		
Quantity:		Refills:		
Directions:				
ı	Diagnosis			
Diagnosis Code:  Diagnosis:  HPP's maximum approval time is 12 months but may be less depending on the drug.				
HPP's maximum approv	rai time is 12 mo	ontris but may be less depending	g on the drug.	
Please attach any pertinent medical history including labs and information for this member that may support approval.				
Please answer the following questions and sign.				
- i				
Q1. Is this a request for Qbrelis (lisinopril oral solution) or Epaned (enalapril oral solution)?				
☐ Yes ☐ No				
Q2. Is the patient less than 9 years of age? [Note: Prior Authorization for Qbrelis (lisinopril oral solution) and Epaned				
(enalapril oral solution) is not required for patients under 9 years of age.]				
☐ Yes	□ No			
Q3. Is this a request for a drug containing aliskiren?				
☐Yes		□ No		
OA to the nations of an appropriate and for the national during a second and the				
Q4. Is the patient of an appropriate age for the requested drug according to Food and Drug Administration (FDA) approved package labeling, nationally recognized compendia, or peer-reviewed medical literature?				
□ Yes				
Q5. Does the patient have a documented diagnosis of uncontrolled hypertension despite treatment with the following				
drug classes at maximally tolerated Food and Drug Administration (FDA) approved doses unless contraindicated: A)				
calcium channel blockers, B) beta blockers, C) diuretics, D) angiotensin-converting enzyme (ACE) inhibitors, E) angiotensin receptor blockers (ARBs)?				
angioterisin receptor blockers (ANDS)!				
Yes		☐ No		
Q6. Is this a request for a preferred angiotensin modulator drug?				
Yes		□ No		
Q7. Does the patient have a documented history of therapeutic failure, contraindication to, or intolerance of the				

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



## HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

## **Angiotensin Modulators**

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:		
preferred angiotensin modulator?			
☐ Yes	□ No		
Q8. Is this a request for an angiotensin modulator drug when there is a record of a recent paid claim for an angiotensin modulator combination drug or another angiotension modulator drug (i.e., potential therapeutic duplication)?			
☐ Yes	□ No		
Q9. Is the patient being titrated to, or tapered from, another angiotensin modulator or angiotensin modulator combination?			
☐ Yes	□ No		
Q10. Has the prescriber provided supporting peer reviewed literature or national treatment guidelines to corroborate concomitant use of the medications being requested?			
☐ Yes	□ No		
Q11. Additional Information:			
Prescriber Signature	 Date		

Updated for 2023